rethinkTHC Search
Menu
Study breakdown

About 80% of medical cannabis users with chronic pain reported substituting it for traditional pain medications

Cross SectionalModerate evidence
The takeaway

In a survey of 1,321 medical cannabis users with chronic pain, approximately 80% reported substituting cannabis for traditional pain medications, including 53% for opioids and 22% for benzodiazepines, citing fewer side effects.

Pain management clinicians, patients with chronic pain, opioid policy researchers, and medical cannabis program administrators.

53% substituted for opioids

What the researchers found

80% of 1,321 medical cannabis users with chronic pain reported substituting cannabis for traditional pain medications: 53% for opioids, 22% for benzodiazepines. Reasons cited were fewer side effects and better symptom management. Experienced users (1+ years) were more likely to take no concomitant pain medications (43% vs 30%) and report improved health (74% vs 67%).

Why it matters

Chronic pain is the most common reason for medical cannabis licenses. If cannabis consistently enables patients to reduce opioid and benzodiazepine use, it has direct implications for the opioid crisis and benzodiazepine dependency epidemic.

The numbers in context

1,321 participants. 80% substituted cannabis for pain meds. 53% for opioids, 22% for benzodiazepines. Medical-only users: older (52 vs 47), less likely to drink (66% vs 79%), more likely to currently take opioids (21% vs 11%). Experienced users: no concomitant meds 43% vs 30%; improved health 74% vs 67%.

How the study worked

Ongoing nationwide online survey of medical cannabis users with chronic pain. 1,321 participants (59% female, 54% aged 50+). Examined effects of cannabis on pain management, health, and medication use, stratified by recreational co-use and duration of cannabis experience.

What this study cannot tell us

Self-reported data from medical cannabis users, biased toward those who found cannabis helpful. No clinical verification of medication changes. Cross-sectional design. No pain severity or functional outcome measures. Cannot determine whether substitution is medically appropriate.

How to read the evidence

Rated moderate because the large sample provides robust descriptive data, though the self-selected population and lack of clinical verification are limitations.

When this study was published

Published in 2019 from an ongoing national survey.

The bigger picture

The high substitution rate and the finding that experienced users are more likely to eliminate other medications suggest cannabis may function as a practical opioid exit ramp for chronic pain patients. The public health implications are significant.

Questions still open

  • Is cannabis substitution for opioids clinically appropriate and safe? Do patients who substitute maintain adequate pain control? What role should physicians play in guiding substitution decisions?

Common questions

Do chronic pain patients replace opioids with cannabis?
In this survey, 53% of medical cannabis users with chronic pain reported reducing or stopping opioid use. An additional 22% substituted cannabis for benzodiazepines.
Why do patients prefer cannabis over traditional pain medications?
Respondents cited fewer side effects and better overall symptom management. Experienced users were more likely to eliminate other pain medications entirely.
Does longer cannabis use lead to better outcomes?
In this study, experienced users (1+ years) were more likely to take no concomitant pain medications (43% vs 30%) and report improved health (74% vs 67%) compared to newer users.

Read the original research

Pills to Pot: Observational Analyses of Cannabis Substitution Among Medical Cannabis Users With Chronic Pain.

The journal of pain, 20(7), 830-841

Citation

Boehnke, Kevin F; Scott, J Ryan; Litinas, Evangelos; Sisley, Suzanne; Williams, David A; Clauw, Daniel J. (2019). Pills to Pot: Observational Analyses of Cannabis Substitution Among Medical Cannabis Users With Chronic Pain.. The journal of pain, 20(7), 830-841. https://doi.org/10.1016/j.jpain.2019.01.010

Explore the wider topic